Nemes Rush Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Nemes Rush Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.36K	Hold	15	–	–	﹤0.01%	744
2026 Q2	$2.37K	Hold	15	–	–	﹤0.01%	769
2026 Q1	$1.92K	Hold	15	–	–	﹤0.01%	754
2025 Q4	$1.83K	Hold	15	–	–	﹤0.01%	751
2025 Q3	$1.5K	Hold	15	–	–	﹤0.01%	612
2025 Q2	$1.24K	Hold	15	–	–	﹤0.01%	636
2025 Q1	$1.22K	Hold	15	–	–	﹤0.01%	640
2024 Q4	$1.35K	Hold	15	–	–	﹤0.01%	645
2024 Q3	$1.42K	Hold	15	–	–	﹤0.01%	532
2024 Q2	$1.39K	Hold	15	–	–	﹤0.01%	537
2024 Q1	$1.42K	Hold	15	–	–	﹤0.01%	585
2023 Q4	$1.34K	Hold	15	–	–	﹤0.01%	580
2023 Q3	$1.1K	Hold	15	–	–	﹤0.01%	580
2023 Q2	$1.25K	Buy	+15	New	+$1.25K	﹤0.01%	595

Other funds holding XBI

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Natixis Paris, France $28B AUM 27.03% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $61B AUM 26.92% 1-Year Est. Return

Williams Jones Wealth Management New York $8.94B AUM 17.99% 1-Year Est. Return

Annex Advisory Services Brookfield, Wisconsin $6.11B AUM 13.75% 1-Year Est. Return

Nemes Rush Group's XBI Position: Q3 2026 in Review

Nemes Rush Group held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q3 2026 at 15 shares worth $2.36K. The position accounts for ﹤0.01% of the portfolio, ranked #744.

Nemes Rush Group first reported a position in XBI in Q2 2023 and has held it in 14 quarters since. The position peaked at $2.37K in Q2 2026. 521 funds tracked by Wall St. Rank hold XBI as of Q3 2026.

Nemes Rush Group held 15 shares of State Street SPDR S&P Biotech ETF worth $2.36K as of Q3 2026.
Nemes Rush Group left its State Street SPDR S&P Biotech ETF share count unchanged in Q3 2026.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of Nemes Rush Group's portfolio in Q3 2026, its #744 holding.
Nemes Rush Group first reported a position in State Street SPDR S&P Biotech ETF in Q2 2023 and has held it in 14 quarters since.
Nemes Rush Group's State Street SPDR S&P Biotech ETF position peaked at $2.37K in Q2 2026.
521 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.

Based on Nemes Rush Group's 13F filing for Q3 2026, filed 4 Nov 2026.